Boehringer Ingelheim Vetmedica Launches Prascend®

Boehringer Ingelheim Vetmedica has launched Prascend®, the first licensed product for the treatment of Pituitary Pars Intermedia Dysfunction (PPID) in horses, commonly known as Equine Cushings Disease. Prascend contains pergolide mesylate, and is supplied in 60 and 160 tablet packs of 1mg tablets. Craig Beck, equine sales and marketing manager at Boehringer Ingelheim Vetmedica, comments: “Many horses and ponies with Cushings Disease benefit from treatment with pergolide, however, with less than 200 people still being treated with pergolide in the UK, many vets and horse owners have expressed concern that they will not be able access treatment in the future. “We have invested in dedicated veterinary manufacturing of this product, and can assure our customers that the future supply of Prascend is guaranteed irrespective of any changes of in the human generic market.” For further information, visit www.prascend.co.uk or call 01344 746959.

More from

• Vetsure Named Business of the Year at 2025 SME National Business Awards
• Home of hope for Romania's dogs: The pioneering shelter doing things differently
• Pioneering new locum platform transforming veterinary landscape
• Key Stakeholders unite to advance helmet design for equine veterinary professionals
• Hallmarq hails transformational equine imaging technology